Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Explore Audio Interview articles from The New England Journal of Medicine ...

A free on-demand webinar where experts deliver high-impact, practical advice to help you manage your patients with obesity confidently and effectively.

Treatment options are limited for patients with advanced triple-negative breast cancer who are not eligible for PD-1 or PD-L1 inhibitors. New research findings on sacituzumab govitecan as first-line ...

Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred ...

The management of carotid-artery stenosis that has not caused recent symptoms — asymptomatic carotid stenosis — has been controversial. Clinical trials that began more than 30 years ago showed a small ...

In the management of breast cancer, treatment approaches are locoregional (i.e., surgery and radiotherapy) or systemic (i.e., chemotherapy, targeted therapy, endocrine therapy, and immunotherapy). The ...

Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...

The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. A comparison of immediate percutaneous coronary ...

A 57-year-old woman with a history of subarachnoid hemorrhage was admitted to the hospital because of visual disturbances involving the right visual field, as well as episodes of shaking of the right ...

As more patients with sickle cell disease or β-thalassemia are treated with the gene-edited cellular drug exa-cel, there are more opportunities to test for potential off-target editing. The authors ...